Harrow, Inc. Stock Issued During Period, Shares, New Issues
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Harrow, Inc. stock issued during period, shares, new issues for the quarter ending 2021-09-30 was 1.57M shares.
- Harrow, Inc. stock issued during period, shares, new issues for the quarter ending 2014-12-31 was 1.05K shares.
- Harrow, Inc. stock issued during period, shares, new issues for the quarter ending 2014-03-31 was 22.28K shares.
- Harrow, Inc. stock issued during period, shares, new issues for fiscal 2021 was 1.57M shares.
- Harrow, Inc. stock issued during period, shares, new issues for fiscal 2014 was 66.44K shares, a 30237.44% increase from fiscal 2013.
- Harrow, Inc. stock issued during period, shares, new issues for fiscal 2013 was 219.00 shares.
- Harrow, Inc. stock issued during period, shares, new issues for fiscal 2009 was 1.14K shares.
| Period end | Stock Issued During Period, Shares, New Issues 3 month | Stock Issued During Period, Shares, New Issues 12 month |
|---|---|---|
| 2021-12-31 | 1.57M shares 10-K · filed 2022-03-10 | |
| 2021-09-30 | 1.57M shares 10-Q · filed 2021-11-09 | |
| 2014-12-31 | 1.05K shares derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-23 | 66.44K shares 10-K · filed 2016-03-23 |
| 2014-03-31 | 22.28K shares 10-Q · filed 2014-05-15 | |
| 2013-12-31 | 219.00 shares 10-K · filed 2015-03-12 | |
| 2009-12-31 | 1.14K shares 10-K · filed 2014-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Kardigan, Inc. (KARD) | United States | $1.346B |